Want to see TFX full AI Analyst Report?
Top Page
Teleflex
(NYSE:TFX)
Select Model
Select Model
Rating:58Neutral
Price Target:
$127.00
▼(-8.46% Downside)
Action:Reiterated
Date:09/09/26
TFX scores in the middle primarily due to weak recent profitability and higher leverage (major financial-performance headwinds), partially offset by resilient and improving free cash flow. The latest earnings call adds support via raised adjusted EPS guidance and deleveraging/buyback execution from the OEM divestiture proceeds, while technicals are neutral-to-slightly positive. Valuation remains a drag given the negative P/E and modest dividend yield.
Positive Factors
Recurring procedure-driven demand
Teleflex benefits from recurring consumable demand embedded in routine and complex hospital procedures. Broad use across vascular access, anesthesia, surgery, urology and critical care can support repeat purchasing, helping make revenue less dependent on one-time capital sales.
Negative Factors
Severe profitability deterioration
The large TTM net loss and declining revenue indicate that recent earnings power has weakened substantially from prior profitable periods. Even with solid gross margin, sustained operating losses can constrain reinvestment, reduce resilience, and make balance-sheet improvement more dependent on execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring procedure-driven demand
Teleflex benefits from recurring consumable demand embedded in routine and complex hospital procedures. Broad use across vascular access, anesthesia, surgery, urology and critical care can support repeat purchasing, helping make revenue less dependent on one-time capital sales.
Read all positive factors
Teleflex Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyTeleflex (TFX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.34B
Dividend Yield1.1%
Average Volume (3M)712.55K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth-14.49%
EPS Growth-644.98%
CountryUS
Employees15,500
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-23.28
Shares Outstanding42,372,400
10 Day Avg. Volume1,003,380
30 Day Avg. Volume712,547
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$157.67Price Target Upside13.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)7.14
Revenue Forecast (FY)$2.27B
Teleflex Business Overview & Revenue Model
Company Description
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within ...
How the Company Makes Money
Teleflex makes money primarily by selling medical devices and related consumables to hospitals, integrated delivery networks, ambulatory surgery centers, and other healthcare providers through direct sales forces and distribution partners, with re...
Teleflex Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 22, 2026
Earnings Call Sentiment Positive
The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.Positive Updates
Revenue and Growth Beat
Q2 continuing operations revenue $570.3M (GAAP up 28.9% YoY) with pro forma adjusted constant currency growth of 4.7%, ahead of expectations.
Negative Updates
Interventional Segment Underperformance and Integration Delays
Interventional revenue $211.9M, down 1.0% YoY. Integration of the VI acquisition is taking longer than planned (order-to-cash, distributor transitions, sales-force realignments), prompting an extended integration timeline through H2 2026 and reduced revenue guidance.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue and Growth Beat
Q2 continuing operations revenue $570.3M (GAAP up 28.9% YoY) with pro forma adjusted constant currency growth of 4.7%, ahead of expectations.
Read all positive updates
Company Guidance
Teleflex updated its 2026 guidance with pro forma adjusted constant‑currency revenue growth narrowed to 3.5%–4.5% (down from 4.5%–5.5%), raised full‑year adjusted EPS to $6.90–$7.20 (prior $6.25–$6.55) and continues to target an adjusted operating margin of ~19% for 2026 (Q2 adj. operating margin was 19.6% and adj. gross margin 61.7%; management’s steady‑state margin target is ~23%); Q2 adj. EPS was $1.76, Q2 adj. net interest expense was $26.5M and FY net interest expense is now expected at ~ $85M (vs. prior ~$105M), the adjusted tax rate is guided to ~12.25% (vs. ~13.5% prior), and shares outstanding are modeled at ~43.3M (excludes the upcoming $250M ASR). On capital allocation and balance sheet metrics, the OEM divestiture generated roughly $1.5B of proceeds (~$1.25B estimated after‑tax) used to pay down a $700M term loan, pro forma net leverage post‑OEM is ~1.9x (quarter‑end net leverage ~2.8x), the company remains committed to a $1.0B buyback program (completed $250M in Q2 repurchasing ~1.9M shares at an average $130.85 and commencing an additional $250M ASR) and an $800M debt reduction goal, and management expects meaningful margin, interest expense and EPS improvement in 2027; modeling assumptions also include an FX tailwind of ~ $14M to 2026 revenue, R&D at 7.9% of sales in H1, ~ $50M of annual pretax restructuring savings by mid‑2028, and no assumed benefit in 2026 guidance from tariff refunds (~$15M applicable to 2026; total expected cash refunds ~ $39M) or proceeds from the pending Acute Care/Interventional Urology divestitures.Teleflex Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
68
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.60B | 1.99B | 3.05B | 2.97B | 2.79B | 2.81B |
| Gross Profit | 1.40B | 1.12B | 1.70B | 1.65B | 1.53B | 1.55B |
| EBITDA | -238.05M | 302.51M | 433.62M | 761.21M | 730.77M | 853.80M |
| Net Income | -1.03B | -905.64M | 69.67M | 356.33M | 363.14M | 485.37M |
Balance Sheet | ||||||
| Total Assets | 6.79B | 6.95B | 7.10B | 7.53B | 6.93B | 6.87B |
| Cash, Cash Equivalents and Short-Term Investments | 300.16M | 393.26M | 306.16M | 222.85M | 292.03M | 445.08M |
| Total Debt | 2.87B | 2.73B | 1.76B | 1.93B | 1.83B | 1.97B |
| Total Liabilities | 3.88B | 3.82B | 2.82B | 3.09B | 2.91B | 3.12B |
| Stockholders Equity | 2.90B | 3.12B | 4.28B | 4.44B | 4.02B | 3.75B |
Cash Flow | ||||||
| Free Cash Flow | 390.63M | 245.44M | 509.31M | 419.20M | 262.95M | 579.80M |
| Operating Cash Flow | 402.44M | 340.68M | 635.74M | 510.64M | 342.14M | 651.42M |
| Investing Cash Flow | -808.05M | -849.19M | -99.36M | -621.23M | -257.94M | 156.74M |
| Financing Cash Flow | 449.36M | 611.54M | -421.93M | 38.54M | -217.51M | -715.82M |
Teleflex Technical Analysis
Neutral
138.74
Price Trends
133.15
Negative
131.71
Negative
123.54
Positive
Market Momentum
-2.85
Negative
43.27
Neutral
72.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TFX, the sentiment is Neutral. The current price of 138.74 is above the 20-day moving average (MA) of 128.50, above the 50-day MA of 133.15, and above the 200-day MA of 123.54, indicating a neutral trend. The MACD of -2.85 indicates Negative momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 72.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TFX.
Teleflex Risk Analysis
Teleflex disclosed 34 risk factors in its most recent earnings report. Teleflex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Teleflex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $5.14B | 34.84 | 9.07% | ― | 10.51% | 20.67% | |
65 Neutral | $48.50B | 53.25 | 3.79% | 2.25% | -2.56% | -40.38% | |
65 Neutral | $3.93B | 132.82 | 1.41% | ― | -8.84% | ― | |
62 Neutral | $635.86M | -17.17 | -21.01% | ― | 9.46% | -6.34% | |
58 Neutral | $5.34B | -5.33 | -31.83% | 1.10% | -14.49% | -644.98% | |
57 Neutral | $12.22B | -11.52 | -16.60% | 0.17% | 5.36% | -632.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TFX
Teleflex
124.12
-5.34
-4.12%
ANGO
AngioDynamics
15.11
3.47
29.81%
BAX
Baxter International
23.49
-0.32
-1.36%
BDX
Becton Dickinson
176.80
28.36
19.11%
ICUI
ICU Medical
159.38
37.31
30.56%
MMSI
Merit Medical Systems
85.37
1.16
1.38%
Teleflex Corporate Events
Business Operations and StrategyExecutive/Board Changes
Teleflex Appoints Sean Salmon to Board, Enhancing Governance
Positive
Sep 9, 2026
On September 8, 2026, Teleflex’s Board of Directors expanded from eight to nine members and elected veteran medical technology executive Sean M. Salmon to the Board, also appointing him to the Growth and Operating Committee. Salmon, who rece...
Business Operations and StrategyStock Buyback
Teleflex Launches $250 Million Accelerated Share Repurchase
Positive
Aug 7, 2026
On August 7, 2026, Teleflex entered into a $250 million accelerated share repurchase agreement with Truist Bank as part of its previously announced $1 billion buyback program, targeting its common stock. The company will pay the repurchase price o...
Business Operations and StrategyStock BuybackFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Teleflex posts strong Q2 2026 results, refines outlook
Positive
Aug 6, 2026
Teleflex reported second-quarter 2026 revenue from continuing operations of $570.3 million, a 28.9% year-on-year increase and 4.7% growth on a pro forma adjusted constant currency basis, with GAAP diluted EPS from continuing operations falling to ...
Business Operations and StrategyStock BuybackM&A Transactions
Teleflex Completes OEM Business Sale to Montagu, Kohlberg
Positive
Aug 3, 2026
On August 3, 2026, Teleflex completed the previously announced sale of its Original Equipment Manufacturing and Development Services business to an affiliate of Montagu and Kohlberg for $1.5 billion in cash. The transaction, conducted via Lotus US...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.